Litcius/Paper detail

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

Luana Calabrò, Giulia Rossi, Aldo Morra, Claudio Rosati, Ornella Cutaia, Maria Grazia Daffinà, Maresa Altomonte, Anna Maria Di Giacomo, Milena Casula, Carolina Fazio, Giuseppe Palmieri, Diana Giannarelli, Alessia Covre, Michele Maio

2021The Lancet Respiratory Medicine44 citationsDOIOpen Access PDF

Topics & Concepts

TremelimumabDurvalumabMedicineMesotheliomaOpen labelInternal medicineOncologyRandomized controlled trialImmunotherapyNivolumabCancerPathologyIpilimumabOccupational and environmental lung diseasesCancer Immunotherapy and BiomarkersMyasthenia Gravis and Thymoma
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study | Litcius